Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin L Jones

Showing results (331-340 of 393) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlatesJanelle M Meyer, Kelly S Perlewitz, James B Hayden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2021
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European studyMahmoud Mohammadi, Nikki S IJzerman, Peter Hohenberger, et al.
Lancet (London, England)|June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialWilliam D Tap, Robin L Jones, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cellsSeth M Pollack, Robin L Jones, Erik A Farrar, et al.
ESMO Open|January 21, 2020
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysisAndrea Napolitano, Salvatore Provenzano, Chiara Colombo, et al.
Cell Reports|January 28, 2014
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversityVanessa Almendro, Yu-Kang Cheng, Amanda Randles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialGeorge D Demetri, Margaret von Mehren, Robin L Jones, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Pageof 40

Showing results (331-340 of 393) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlatesJanelle M Meyer, Kelly S Perlewitz, James B Hayden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
The Lancet. Oncology|June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyFederica Grosso, Robin L Jones, George D Demetri, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2021
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European studyMahmoud Mohammadi, Nikki S IJzerman, Peter Hohenberger, et al.
Lancet (London, England)|June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialWilliam D Tap, Robin L Jones, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cellsSeth M Pollack, Robin L Jones, Erik A Farrar, et al.
ESMO Open|January 21, 2020
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysisAndrea Napolitano, Salvatore Provenzano, Chiara Colombo, et al.
Cell Reports|January 28, 2014
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversityVanessa Almendro, Yu-Kang Cheng, Amanda Randles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialGeorge D Demetri, Margaret von Mehren, Robin L Jones, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Pageof 40